Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Lee430on May 13, 2023 8:49pm
84 Views
Post# 35447156

RE:RE:AGM was horrible

RE:RE:AGM was horribleAny thoughts on when we might start to see our board making some overdue changes after the AGM votes made our concerns unmistakenly and clear?

SPCEO1 wrote: I would not like to see you potentially make a decision you might shortly come to regret. We are likely three weeks away from the FDA giving them their approval to restart TH-1902. Then they have promised a conference call to fully discuss the phase 1b trial. The stock was more than double the currnt price when the phase 1b was in progress previously so I would not be surprised to see the stockk price react positively to those two developments.

I agree Paul, in particular was giving off a lot of bad body language at the AGM. But you need to consider they had narrowly avoided getting voted out by shareholders. Had myself and a group of friends decided simply not to vote, let alone vote against the proposals at the AGM, the board would have needed to be reconstituted. We chose to vote for them after a good conversation with the board chair and we are hopeful our support for them will be followed by action on the suggestions we made. If not, there are alternatives available which we really doubt will need to be utilized. The board certainly heard from all shareholders via the votes and our conversation and to not act to make changes after that really would be far afield from the "decisive action and agile tactics" Paul talked about at the AGM.
 
Trogarzon wrote: I relistened the AGM call once again.  So bad, so unenthusiastic at a time the stock price needs a pep talk.  My gut tells me to sell this time around since they are clearly bad at what they do.  Sorry I will sell my block because I personnally think they will deep six the company in dept and numerous bad decisions.  It's their story and it will perpetuate in the prsent form.  




<< Previous
Bullboard Posts
Next >>